ICU Management of Invasive β-Hemolytic Streptococcal Infections

Ahmed Babiker; Sameer S Kadri

doi:10.1016/j.idc.2022.07.007

ICU Management of Invasive β-Hemolytic Streptococcal Infections

Infect Dis Clin North Am. 2022 Dec;36(4):861-887. doi: 10.1016/j.idc.2022.07.007.

Authors

Ahmed Babiker¹, Sameer S Kadri²

Affiliations

¹ Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA; Department of Laboratory Medicine and Pathology, Emory University School of Medicine.
² Critical Care Medicine Department, Clinical Epidemiology Section, National Institutes of Health Clinical Center, Bethesda, MA, USA. Electronic address: sameer.kadri@nih.gov.

PMID: 36328640
DOI: 10.1016/j.idc.2022.07.007

Abstract

β-hemolytic streptococci (BHS) are a leading cause of invasive bacterial disease worldwide. They are subtyped based on the presence of the surface polysaccharide antigens and include Group A Streptococcus (GAS; Streptococcus pyogenes), Group B Streptococcus (GBS; Streptococcus agalactiae), and non-group A, non-group B Streptococci (NABS). Invasive BHS infection is defined as isolation from the normally sterile site in patients with a compatible clinical syndrome which include, but is not limited to, streptococcal toxic shock syndrome (STSS), Necrotizing soft tissue infection (NSTI), bacteremia, meningitis lower respiratory tract, musculoskeletal and puerperal/postpartum infections. Resuscitation, source control, and β-lactam therapy are the cornerstone of therapy.

Keywords: Invasive streptococcal infection; Necrotizing fasciitis; Necrotizing soft tissue infection; STSS; Streptococcal toxic shock syndrome.

Publication types

Review

MeSH terms

Female
Humans
Intensive Care Units
Shock, Septic* / drug therapy
Shock, Septic* / microbiology
Soft Tissue Infections* / microbiology
Streptococcal Infections* / drug therapy
Streptococcal Infections* / microbiology
Streptococcus pyogenes